Cocrystal Pharma, Inc. - COCP STOCK NEWS

Cocrystal Pharma (Nasdaq: COCP) will present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021, at 2:00 p.m. ET in Jupiter, Florida. The company recently received regulatory clearance from an Australian Human Research Ethics Committee to start a Phase 1 trial for its orally administered CC-42344 drug targeting influenza A. CFO James Martin expressed enthusiasm for discussing the company's COVID-19 antiviral programs during the presentation. A live and archived webcast will be available on the company's website.

Cocrystal Pharma (Nasdaq: COCP) has received clearance from an Australian Human Research Ethics Committee to commence a Phase 1 trial of its orally administered PB2 inhibitor CC-42344 for treating pandemic and seasonal influenza A. The randomized, double-blind, placebo-controlled study will enroll 56 healthy volunteers in Australia, focusing on the drug's safety, tolerability, and pharmacokinetics. CC-42344 exhibits exceptional antiviral activity against various influenza strains, addressing the urgent need for effective antiviral treatments.

Cocrystal Pharma, a clinical-stage biotechnology company, announced its participation in the 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast of the presentation will be available on its website starting at 1:00 a.m. ET on September 13.

Management will discuss advancements in antiviral programs targeting SARS-CoV-2 and influenza. Notable developments include the anticipated initiation of a Phase 1 trial for CC-42344 for influenza A treatments, with IND-enabling studies expected in early 2022.

Cocrystal Pharma (Nasdaq: COCP) reported no revenues for Q2 2021, down from $554,000 in Q2 2020, as Merck has assumed all development expenses for their influenza A/B program. The company's R&D expenses rose to $2.7 million, reflecting investments in COVID-19 and influenza programs. Cocrystal has $67 million in cash, sufficient to fund operations beyond 2024. Upcoming milestones include the initiation of Phase 1 clinical trials for CC-42344 and IND-enabling studies for COVID-19 antiviral compounds in 2022, after encouraging preclinical results.

Cocrystal Pharma (Nasdaq: COCP) announced that its SARS-CoV-2 protease inhibitor, CDI-45205, along with its analogs, showed strong in vitro efficacy against the Delta and Gamma variants of SARS-CoV-2. Previously, this compound demonstrated broad-spectrum activity against other variants, indicating potential as a treatment for COVID-19. Cocrystal plans to scale up synthesis for IND-enabling studies to bring CDI-45205 into clinical trials. The company's continued development of oral protease inhibitors aims to create effective coronavirus antivirals.

Cocrystal Pharma, Inc. (Nasdaq: COCP) has been added to the Russell Microcap® Index as of June 28, 2021. This addition marks a significant milestone, enhancing the company’s visibility in the investment community. The company focuses on developing novel antiviral therapeutics targeting various viruses, including influenza and coronaviruses. Cocrystal plans to initiate a Phase 1 trial for influenza A in Q3 2021. Membership in the index is based on market capitalization and style attributes and remains valid for one year.

Cocrystal Pharma (Nasdaq: COCP) has completed IND-enabling studies for its broad-spectrum PB2 inhibitor, CC-42344, aimed at treating seasonal and pandemic influenza A. The company plans to initiate a Phase 1 clinical trial in Australia in Q3 2021. A 14-day GLP toxicology study has confirmed the drug's safety prior to human trials. This antiviral has the potential to overcome challenges posed by existing treatments that are vulnerable to resistance. The World Health Organization estimates that seasonal influenza affects 1 billion people annually, highlighting the need for effective antiviral solutions.

Cocrystal Pharma (Nasdaq: COCP) announced that its lead preclinical SARS-CoV-2 3CL protease inhibitor, CDI-45205, shows potent activity against SARS-CoV-2 and two variants, B.1.1.7 and B.1.351. In vitro studies revealed CDI-45205 had an EC50 of 1.9 uM against the UK variant and 2.5 uM against the South African variant, outperforming comparator drugs like remdesivir. Cocrystal aims to further test CDI-45205 against emerging variants, reinforcing its potential as a COVID-19 treatment.

Cocrystal Pharma (Nasdaq: COCP) announced that management's participation in the Noble Capital Markets C-Suite Interview Series is now available online. The discussion covered their antiviral drug development programs targeting various viruses, with upcoming milestones including a proof-of-concept study for norovirus and a Phase 1 study for influenza A planned for Q3 2021. Interim co-CEO James Martin stated that the company has sufficient capital to fund operations through 2024, without the expectation of raising additional capital in 2021.